This is a real report excerpt from an actual dodilligence run on Palantir Technologies — not a fictional company. Every fact below was collected from public sources (SEC EDGAR, Wikipedia, Wikidata, news, company website). Paid orders deliver a full 10–20 page PDF with all 16 sections. Not legal or financial advice.
Stance: Conditional proceed — expand data room before capital commit. High confidence (multi-source public synthesis + structured pack).
Source: Wikipedia, Wikidata (Q2047336), SEC EDGAR, company website — all verified by multi-source collector.
| Date | Form type | Accession | What it signals |
|---|---|---|---|
| 2026-07-07 | Form 4 | 0001824159-26-000009 | Insider transaction |
| 2026-07-02 | Form 144 | 0001969223-26-000758 | Proposed insider sale |
| 2026-07-01 | Schedule 13G | 0001321655-26-000036 | Major holder disclosure |
| 2026-06-17 | Form 4 | 0001823952-26-000016 | Insider transaction |
| 2026-06-15 | Form 4 | 0001705189-26-000011 | Insider transaction |
| 2026-06-09 | 8-K | — | Material event disclosure |
Full paid report includes 36-month filing history, financial statement extracts, and material-event analysis. SEC link: EDGAR CIK 1321655
Screening a real target? Same multi-source pipeline — SEC filings, news, Wikipedia, Wikidata, company site, web search. $49 after Stripe, PDF in 3–24s (median 15s · 4 real orders).
Order $39.20 →| Severity | Risk | Description | Likelihood |
|---|---|---|---|
| High | Information asymmetry | Thin public data increases chance of hidden liabilities. | High |
| High | Customer concentration | Government contract concentration — verify in data room. | Med-High |
| High | Key-person risk | Founder-led (Karp/Thiel) — common in visionary companies. | Med |
| Medium | Competitive displacement | Snowflake, Databricks, hyperscaler analytics — requires peer teardown. | Med |
| Medium | Regulatory / surveillance ethics | Government contracts subject to political and policy shifts. | Med |
| Medium | Contract / IP defects | Standard private-to-public diligence — verify assignment chain. | Med |
Full paid report includes heat-map interpretation and mitigation recommendations for each risk.
| Workpaper | Owner | Priority |
|---|---|---|
| Historical P&L (36 months) | Target CFO | P0 |
| Balance sheet + debt schedule | Target CFO | P0 |
| Cash flow / bank statements sample | Target | P0 |
| Revenue cohort / retention | RevOps | P1 |
| Customer concentration (top 10 + %) | Sales ops | P0 |
| Pipeline & win/loss (4 quarters) | CRO | P1 |
| Timing | Action |
|---|---|
| Day 1–2 | Entity verification, web/registry sweep, news/litigation scan refresh |
| Day 3–5 | Document request list issued; kickoff with management |
| Week 2 | Financial workpapers + customer concentration analysis |
| Week 2–3 | 3–5 expert/customer calls; competitor teardown |
| Week 3–4 | Legal/IP review with outside counsel; risk register final |
| Week 4 | IC memo with go / no-go / re-trade recommendations |
Full paid report includes 40+ cited sources with URLs. Every claim is source-linked in the PDF.
This is a real excerpt — not a mockup. The full 16-section report on Palantir (or any company you need) runs through the same pipeline. 10–20 page PDF, every claim cited, delivered 3–24s after Stripe (median 15s · 4 real orders).
Get this on your target — $39.20 →Compare with other samples:
© 2026 dodilligence.io. This sample report is for evaluation purposes only — not legal, investment, or accounting advice. All data sourced from public information. Palantir Technologies Inc. is a third-party public company; this report is not endorsed by or affiliated with Palantir. Full Terms: dodilligence.io/terms